GETI.B

199.05

-0.43%↓

ATT

100.4

-0.99%↓

AMBEA

123.1

-0.08%↓

ARJOB

26.8

-0.74%↓

MSON.B

11.65

0%↓

GETI.B

199.05

-0.43%↓

ATT

100.4

-0.99%↓

AMBEA

123.1

-0.08%↓

ARJOB

26.8

-0.74%↓

MSON.B

11.65

0%↓

GETI.B

199.05

-0.43%↓

ATT

100.4

-0.99%↓

AMBEA

123.1

-0.08%↓

ARJOB

26.8

-0.74%↓

MSON.B

11.65

0%↓

GETI.B

199.05

-0.43%↓

ATT

100.4

-0.99%↓

AMBEA

123.1

-0.08%↓

ARJOB

26.8

-0.74%↓

MSON.B

11.65

0%↓

GETI.B

199.05

-0.43%↓

ATT

100.4

-0.99%↓

AMBEA

123.1

-0.08%↓

ARJOB

26.8

-0.74%↓

MSON.B

11.65

0%↓

Home・Akcijų sąrašas・Vivesto AB

Vivesto AB

Atidarymo kaina

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

Max

Pagrindiniai rodikliai
By Trading Economics
Pajamos	2.3M -7.2M
Pelnas, tenkantis vienai akcijai	-0.013
Darbuotojai	4
EBITDA	-7.1M

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-27

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-27M 51M
Ankstesnė atidarymo kaina	0
Ankstesnė uždarymo kaina	0

Vivesto AB Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-24 23:07; UTC

Uždarbis

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026-02-24 23:01; UTC

Uždarbis

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026-02-24 22:59; UTC

Uždarbis

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

2026-02-24 22:42; UTC

Uždarbis

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

2026-02-24 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

2026-02-24 23:46; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

2026-02-24 23:36; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

2026-02-24 23:30; UTC

Rinkos pokalbiai

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

2026-02-24 23:20; UTC

Rinkos pokalbiai

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

2026-02-24 23:20; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-24 23:16; UTC

Uždarbis

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

2026-02-24 23:13; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

2026-02-24 23:12; UTC

Uždarbis

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

2026-02-24 23:10; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

2026-02-24 23:10; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

2026-02-24 23:08; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

2026-02-24 23:07; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

2026-02-24 22:52; UTC

Uždarbis

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026-02-24 22:46; UTC

Uždarbis

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026-02-24 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Warner Receives New Bid From Paramount -- 3rd Update

2026-02-24 22:29; UTC

Uždarbis

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

2026-02-24 22:28; UTC

Uždarbis

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

2026-02-24 22:27; UTC

Uždarbis

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

2026-02-24 22:27; UTC

Uždarbis

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

2026-02-24 22:25; UTC

Uždarbis

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

2026-02-24 22:24; UTC

Uždarbis

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

2026-02-24 22:23; UTC

Uždarbis

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

2026-02-24 22:22; UTC

Uždarbis

Woolworths Interim Dividend 45 Australian Cents/Share

2026-02-24 22:22; UTC

Uždarbis

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

2026-02-24 22:21; UTC

Uždarbis

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Akcijų palyginimas

Kainos pokytis

Vivesto AB Prognozė

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.